101. Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?
- Author
-
Yu W, Wang L, Han N, Zhang X, Mahapatra T, Mahapatra S, Babu GR, Tang W, Detels R, and Zhao J
- Subjects
- Cost-Benefit Analysis, Drug Combinations, Emtricitabine administration & dosage, Female, HIV Infections transmission, HIV Infections virology, Humans, Male, Randomized Controlled Trials as Topic, Risk-Taking, Tenofovir administration & dosage, Treatment Outcome, Anti-HIV Agents administration & dosage, HIV Infections prevention & control, Patient Compliance psychology, Pre-Exposure Prophylaxis economics, Sexual Behavior psychology
- Abstract
Antiretroviral drugs are being tried as candidates for the pre-exposure prophylaxis (PrEP) against HIV for a considerable period, due to their potential for immediate inhibition of viral replication. Discrepancies in the findings called for a critical review of the relevant efforts and their outcomes. A systematic literature search identified 143 eligible articles of which only 5 reported complete findings while another 11 were still on-going. Observed moderate efficacy and good safety profile seemed to identify PrEP as a promising step for minimizing the spread of HIV to relatively unaffected population and controlling the epidemic among high risk population groups. But the duration of this efficacy was found to depend heavily on the availability, adherence and other related issues like cost, political commitment, ethical consideration etc. To prevent potential cultural and behavioral modifications, proper pre-administration counseling also seemed critical for the success of PrEP as a cost-effective intervention with adequate coverage.
- Published
- 2016
- Full Text
- View/download PDF